AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31813230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 31813230 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 171
Study 31427542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical-load condition
Number of subjects: 52
Study 31427542 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating low to moderate physical-load condition
Number of subjects: 52
Study 31427542 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical-load condition
Number of subjects: 52
Study 31427542 — intervention group
Group type: COMPARATOR
Intervention: No physical-load condition
Number of subjects: 52
Study 27893182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (300 mg)
Number of subjects: 60
Study 27893182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (40 mg)
Number of subjects: 60
Study 27893182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (300 mg) with clarithromycin
Number of subjects: 60
Study 27893182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (40 mg) with clarithromycin
Number of subjects: 60
Study 25589534 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes or impaired fasting glucose
Number of subjects: 373
Study 25589534 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose
Number of subjects: 373
Study 25589534 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 373
Study 25589534 — intervention group
Group type: COMPARATOR
Intervention: Normal fasting glucose
Number of subjects: 373
Study 24018226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 135
Study 24018226 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 135
Study 24018226 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 135
Study 21514308 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute angiotensin II receptor blocker (ARB; 600 mg irbesartan)
Number of subjects: 17
Study 21514308 — intervention group
Group type: COMPARATOR
Intervention: Acute calcium channel blockade (CCB; 10mg felodipine ER)
Number of subjects: 17
Study 21514308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18063834 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant individuals
Number of subjects: 0
Study 18063834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive load
Number of subjects: 0
Study 16307846 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer smoking tips
Number of subjects: 43
Study 16307846 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 43
Study 14603161 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic RH
Number of subjects: 469
Study 14603161 — intervention group
Group type: COMPARATOR
Intervention: Open RH
Number of subjects: 469
Study 14603161 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic LH
Number of subjects: 469
Study 14603161 — intervention group
Group type: COMPARATOR
Intervention: Open LH
Number of subjects: 469
Study 11145799 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoles containing mineral derivatives
Number of subjects: 169
Study 11145799 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 169
Study 8636182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg body-weight, intravenously before tourniquet release and repeated three hours later)
Number of subjects: 86
Study 8636182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86
Study 8636182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 86
Study 8636182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid and Placebo
Number of subjects: 86
Study 1450477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane (CU) bicarbonate hemodialysis
Number of subjects: 6
Study 1450477 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone (PS) bicarbonate hemodialysis
Number of subjects: 6
Study 6380565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 506
Study 6380565 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study 31622473 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent sequences
Number of subjects: 0
Study 31622473 — intervention group
Group type: COMPARATOR
Intervention: Random order sequences
Number of subjects: 0
Study 31622473 — intervention group
Group type: COMPARATOR
Intervention: Phase-randomized scenes
Number of subjects: 0
Study 30389894 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable predictive model based on baseline covariates and follow-up data
Number of subjects: 0
Study 26842871 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced multidisciplinary self‐management patient education program
Number of subjects: 566
Study 26842871 — intervention group
Group type: COMPARATOR
Intervention: Standard patient education programs
Number of subjects: 566
Study 24274030 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-enriched solution (H2‐HD)
Number of subjects: 8
Study 24274030 — intervention group
Group type: COMPARATOR
Intervention: Standard solution
Number of subjects: 8
Study 23211655 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic case report forms (eCRF)
Number of subjects: 760
Study 23211655 — intervention group
Group type: COMPARATOR
Intervention: Paper-based case report forms (CRF)
Number of subjects: 760
Study 20675426 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 As (Ask, Advise, Assess, Assist, Arrange)
Number of subjects: 2160
Study 20675426 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 As (AAR model)
Number of subjects: 2160
Study 20675426 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2160
Study 20675426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention conditions (5 As and 3 As)
Number of subjects: 2160
Study 17414000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular cooling catheter (Coolgard, Alsius, CA)
Number of subjects: 26
Study 17414000 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (antipyretic drugs and/or surface cooling techniques)
Number of subjects: 26
Study 16335643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision screening by trained school nurses
Number of subjects: 1719
Study 16335643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision test sensitivity in females, older students, and North Sharqiya region
Number of subjects: 1719
Study 16335643 — intervention group
Group type: EXPERIMENTAL
Intervention: General vision screening of school students in Oman
Number of subjects: 1719
Study 16335643 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic training of nurses and supervision of screening procedures
Number of subjects: 1719
Study 11703862 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous whole blood (WB)
Number of subjects: 97
Study 11703862 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fresh-frozen plasma and buffy coat-poor red cells (RC)
Number of subjects: 97
Study 11703862 — intervention group
Group type: COMPARATOR
Intervention: No transfusion (NT)
Number of subjects: 97
Study 9131646 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 12
Study 9131646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8074963 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 3446275 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol at 200 mg bd
Number of subjects: 3052
Study 3446275 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 3052
Study 3446275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-trial non-smokers (NS)
Number of subjects: 3052
Study 29540274 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1 g/d)
Number of subjects: 14
Study 29540274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 26717881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.1, 0.2, 0.3, or 0.4 mg doses)
Number of subjects: 26
Study 26717881 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 26
Study 25847577 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health Jr. (HH) intervention
Number of subjects: 0
Study 25847577 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health Jr. Obesity Prevention Effectiveness Trial (HH Effectiveness)
Number of subjects: 0
Study 25847577 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) study
Number of subjects: 0
Study 23095194 — intervention group
Group type: EXPERIMENTAL
Intervention: Leakection
Number of subjects: 200
Study 23095194 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioquick
Number of subjects: 200
Study 20943209 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM
Number of subjects: 2907
Study 20943209 — intervention group
Group type: COMPARATOR
Intervention: MCV4
Number of subjects: 2907
Study 20943209 — intervention group
Group type: COMPARATOR
Intervention: MenACWY‐CRM and MCV4
Number of subjects: 2907
Study 18580398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) - Lo/Ovral (30 microg of ethinyl estradiol and 0.3 mg of norgestrel)
Number of subjects: 150
Study 18580398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 16776446 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid (INH) 300 mg
Number of subjects: 40
Study 16776446 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 40
Study 16776446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg
Number of subjects: 40
Study 16776446 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 1000 mg
Number of subjects: 40
Study 16776446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (moxifloxacin, gatifloxacin, levofloxacin)
Number of subjects: 40
Study 14653287 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned with 20% polyacrylic acid for 10 seconds
Number of subjects: 42
Study 14653287 — intervention group
Group type: COMPARATOR
Intervention: No surface treatment (control)
Number of subjects: 42
Study 14653287 — intervention group
Group type: EXPERIMENTAL
Intervention: Etched with 37% phosphoric acid for 15 seconds
Number of subjects: 42
Study 10334255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 199
Study 10334255 — intervention group
Group type: COMPARATOR
Intervention: Single drug therapy (sulphasalazine, with or without methotrexate and prednisolone)
Number of subjects: 199
Study 8944991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF) with a polysulfone ultrafiltrator before extracorporeal circulation
Number of subjects: 17
Study 8944991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 17
Study 1673592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.04 mg/kg
Number of subjects: 20
Study 1673592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.07 mg/kg
Number of subjects: 20
Study 7081646 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 36
Study 7081646 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene
Number of subjects: 36
Study 7081646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extradural anaesthesia
Number of subjects: 36
Study 29773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc, magnesium, and chromium supplementation (300 mg magnesium, 600 μg chromium, 36 mg zinc per day)
Number of subjects: 32
Study 29773176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26854810 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 150mg once daily with darunavir/ritonavir
Number of subjects: 797
Study 26854810 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine once daily with darunavir/ritonavir
Number of subjects: 797
Study 24371012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 24371012 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study 22743661 — intervention group
Group type: EXPERIMENTAL
Intervention: CBIT delivered over videoconference
Number of subjects: 20
Study 22743661 — intervention group
Group type: COMPARATOR
Intervention: CBIT via traditional face-to-face delivery
Number of subjects: 20
Study 20433042 — intervention group
Group type: EXPERIMENTAL
Intervention: BT/ER curriculum participants
Number of subjects: 0
Study 20433042 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants completing at least 45 hours of training in the past year
Number of subjects: 0
Study 20433042 — intervention group
Group type: COMPARATOR
Intervention: Participants who did not report significant amounts of training
Number of subjects: 0
Study 18768506 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of one or more sexually transmissible infections (STIs)
Number of subjects: 868
Study 18768506 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA antibody to Chlamydia trachomatis
Number of subjects: 868
Study 18768506 — intervention group
Group type: COMPARATOR
Intervention: Individual STIs (Chlamydia trachomatis, HPV-16 and -18, herpes simplex virus-2, cytomegalovirus, human herpesvirus-8)
Number of subjects: 868
Study 15857076 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Tooth (TT)
Number of subjects: 17
Study 15857076 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral Tooth (CT)
Number of subjects: 17
Study 15857076 — intervention group
Group type: COMPARATOR
Intervention: Antagonist Tooth (AT)
Number of subjects: 17
Study 12423714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg 3 times daily)
Number of subjects: 18
Study 12423714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10412786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and azathioprine
Number of subjects: 216
Study 10412786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and cyclosporine
Number of subjects: 216
Study 10412786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, azathioprine, and cyclosporine
Number of subjects: 216
Study 10412786 — intervention group
Group type: COMPARATOR
Intervention: Healthy, age‐ and sex‐matched subjects
Number of subjects: 216
Study 10412786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (dose-dependent)
Number of subjects: 216
Study 10412786 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall immunosuppressive therapy
Number of subjects: 216
Study 10412786 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL triglyceride/apo B ratio
Number of subjects: 216
Study 10412786 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum cholesterol
Number of subjects: 216
Study 7567321 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intervention (hospital packet + oral and written advice at 2 weeks, 2, 4, and 6 months)
Number of subjects: 2901
Study 7567321 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (hospital packet only)
Number of subjects: 2901
Study 2145235 — intervention group
Group type: EXPERIMENTAL
Intervention: enoximone, 150 mg t.d.s.
Number of subjects: 10
Study 2145235 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 7387340 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of haloperidol on day 1, increasing increments of 20 mg daily, maximum 100 mg daily on day 5
Number of subjects: 63
Study 7387340 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of haloperidol on day 1, increasing increments of 10 mg daily, maximum 100 mg daily on day 10
Number of subjects: 63
Study 7387340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dosage of 10 mg daily for ten days
Number of subjects: 63
Study 6133525 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (single administration)
Number of subjects: 85
Study 6133525 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen (reference substance)
Number of subjects: 85
Study 6133525 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (seven days of treatment)
Number of subjects: 85
Study 6133525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (seven days of treatment)
Number of subjects: 85
Study 30959123 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-neoAS, pre-RT PSA level >0.1 ng/mL
Number of subjects: 2404
Study 30148430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 2.5% cross-linked polyacrylamide hydrogel (PAAG), 3 ml, up to two injections 1 month apart.
Number of subjects: 84
Study 26916483 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 9236
Study 26916483 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 9236
Study 26916483 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 metabolizer status
Number of subjects: 9236
Study 24968790 — intervention group
Group type: EXPERIMENTAL
Intervention: HS219 (40 mg chitosan‐loaded chewing gum)
Number of subjects: 68
Study 24968790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 24968790 — intervention group
Group type: EXPERIMENTAL
Intervention: HS219
Number of subjects: 68
Study 22490690 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection (LR)
Number of subjects: 108
Study 22490690 — intervention group
Group type: COMPARATOR
Intervention: Conventional open resection (OR)
Number of subjects: 108
Study 20703158 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc once daily
Number of subjects: 1049
Study 20703158 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc twice daily
Number of subjects: 1049
Study 20703158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1049
Study 18827119 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mg drospirenone/20-microgram ethinyl estradiol 24/4 regimen
Number of subjects: 538
Study 18827119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 16054802 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 0
Study 16054802 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (4-12 mg/day)
Number of subjects: 0
Study 11807486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant-supported overdentures (IOD)
Number of subjects: 68
Study 11807486 — intervention group
Group type: COMPARATOR
Intervention: Conventional mandibular dentures (CD)
Number of subjects: 68
Study 10987630 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet tailored to smoking patterns, stage of change, and lifestyle of pregnant smokers
Number of subjects: 390
Study 10987630 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet plus access to a computerized telephone cessation program based on interactive voice response technology
Number of subjects: 390
Study 10987630 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet plus proactive telephone counseling from nurse educators using motivational interviewing techniques and strategies
Number of subjects: 390
Study 10987630 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care advice from prenatal providers)
Number of subjects: 390
Study 7726807 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal training (combining the alarm device with reinforcement for correct behaviour)
Number of subjects: 113
Study 7726807 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (other means without alarm device)
Number of subjects: 113
Study 2150025 — intervention group
Group type: EXPERIMENTAL
Intervention: legume-supplemented normal caloric diet for 8 weeks
Number of subjects: 40
Study 2150025 — intervention group
Group type: COMPARATOR
Intervention: usual diet
Number of subjects: 40
Study 7310594 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 18
Study 7310594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no caffeine treatment)
Number of subjects: 18
Study 31757470 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 432
Study 31757470 — intervention group
Group type: EXPERIMENTAL
Intervention: TMI
Number of subjects: 432
Study 31181973 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line pembrolizumab monotherapy
Number of subjects: 386
Study 31181973 — intervention group
Group type: COMPARATOR
Intervention: KEYNOTE-024 (KN024)
Number of subjects: 386
Study 31181973 — intervention group
Group type: COMPARATOR
Intervention: KEYNOTE-042 (KN042)
Number of subjects: 386
Study 29191325 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure with the Amplatzer PFO Occluder device
Number of subjects: 230
Study 29191325 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy with a sham procedure (right heart catheterization)
Number of subjects: 230
Study 25526831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 sessions
Number of subjects: 33
Study 25526831 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 33
Study 25526831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 33
Study 24180003 — intervention group
Group type: EXPERIMENTAL
Intervention: MAALES intervention
Number of subjects: 437
Study 24180003 — intervention group
Group type: COMPARATOR
Intervention: Control group (single, individualized HIV risk-reduction session)
Number of subjects: 437
Study 22011688 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (100 - 400 mg/d)
Number of subjects: 1046
Study 22011688 — intervention group
Group type: COMPARATOR
Intervention: Active comparators
Number of subjects: 1046
Study 22011688 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 1046
Study 18696272 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale (mRS) scores
Number of subjects: 820
Study 18696272 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index (BI) scores
Number of subjects: 820